Navigation Links
Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovio's Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
Date:7/18/2013

out Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its synthetic consensus design approach is intended to help the immune system identify and fight cancer cells or multiple unmatched strains of a mutating virus. These proprietary synthetic vaccines, in combination with Inovio's electroporation delivery, have in humans generated best-in-class immune responses with a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused diseases, is in phase II. Other phase I and preclinical programs focus on HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and tha
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Varian Medical Systems to Exhibit Flat Panel Detectors, X-Ray Tubes and Imaging Software Optimized for Digital Radiography at CMEF
2. Varian Medical Systems to Exhibit Flat Panel Detectors, X-Ray Tubes and Imaging Software Optimized for Digital Radiography at MEDICA
3. Cerulean Pharma to Present Data on CRLX101s HIF-1a Inhibition at the American Association for Cancer Research Annual Meeting
4. CoMentis and Anvyl Announce Formation of Alpharmagen, a Joint Venture to explore Nicotinic Modulators
5. ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
6. Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt
7. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
8. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
9. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
10. Alphaport Named Winner of CorpUs Excellence and Innovation Award
11. Sophono Alpha 2 Hearing System Receives FDA Clearance for Use With MRI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Publicis Groupe customer engagement agency ... and Healthcare Industry Group Leader, has been featured in ... most inspiring people in the life-sciences industry. Those chosen ... development, marketing, technology, creativity, strategy and medicine. ... partner in its leading Rosetta Consulting practice. In 2012, ...
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- ScriptPro has been certified ... its Common Security Framework (CSF). According to ... Manager, "We appreciate this rigorous, top-to-bottom audit. Security-minded ... this certification signifies. Our business partners need to ... CSF CERTIFICATION PROCESS: ScriptPro,s internal security processes and ...
Breaking Medicine Technology:Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2
... Johnson & Johnson (NYSE: JNJ ) today ... & Diagnostics (MD&D) and Sheri McCoy, currently Worldwide Chairman, ... Committee and join William C. Weldon, Chairman of the ... of the Chairman.  Both appointments are effective January 3, ...
... LAKE FOREST, Ill., Dec. 15, 2010 RoundTable ... focused exclusively on the healthcare industry, announced today ... to sell one of its portfolio companies, Clinical ... private investment firm representing Pritzker family interests.  Terms ...
Cached Medicine Technology:Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced ... shorter progression free survival (PFS) in epidermal growth ... chemotherapy treated Asian patients. Also, BIM deletion independently ... , The BIM protein can activate the programmed ... in cells. BIM deletion has been detected in ...
(Date:8/22/2014)... Rheumatoid arthritis (RA), a complex autoimmune disease that ... patients to not only cope with pain, disability ... as disrupted work, family life and marital functioning. ... residual pain and disability is common. In addition, ... high cost or side effects. Because of this, ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Advancements ... for some clinical applications due to their cost-effectiveness, ... emerging innovations in ultrasound, such as the evolution ... expected to keep the market moving throughout 2014 ... mobility can enhance not only the point-of-care (POC) ...
(Date:8/22/2014)... Sac, Wisconsin (PRWEB) August 22, 2014 ... System for Plantar Fasciitis, an exciting new product that ... allows you to stay active while you heal. The ... This is truly a new technology – it is ... affordable. , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
(Date:8/22/2014)... intensive effort to sterilize feral cats reduced the number of ... a new study reveals. "We investigated whether we ever ... control," Dr. Julie Levy, a professor of shelter medicine at ... a university news release. "Neutering a few cats ... "so we wanted to pick a focused area and throw ...
Breaking Medicine News(10 mins):Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Neutering Project Curbed Feral Cat Population 2
... a potential heart attack risk? According to a recent study, ... with the strengthening of the US economy., ,Christopher Ruhm, ... Greensboro wrote in his study that there is a pronounced ... economy grows further with no improvement in the rate of ...
... to a study conducted by the University of Erfurt ... willing to inflict financial pain to achieve// collective gain. ... ,Researchers have found that groups in ... were more popular than groups without this option. Though ...
... According to experts approximately 6,000 plus trampolining fractures were ... for new safety guidelines// are needed to stem the ... in a study has found a "worrying trend" in ... in the home. ,The Royal Berkshire in ...
... doesn’t seem to have learnt its lessons yet, because there ... of AIDS/HIV//. Next only to South Africa with the highest ... million mark as per statistics in 2003, very little has ... AIDS/HIV cases, according to Prof Suzanne Crowe, Deputy Chairperson of ...
... Pharma has come up with a new neupro skin patch ... It is said to offer relief to patients// in the ... mimics the effects of a naturally occurring brain chemical, which ... ,The Parkinson's Disease Society said that the patch would aid ...
... It’s learning time for countries, and Vietnam’s tryst with ... management//. Vietnamese Farmers appear to know much more about ... their counterparts in Europe and Africa. Not surprising, since ... the onslaught of bird-flu, which in 2003 had claimed ...
Cached Medicine News:Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 2Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 3Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 4Health News:Be cautious while on the Trampoline 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: